Cutler Group LP Viking Therapeutics, Inc. Put Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 Apr 19, 2024	SELL	$17.4 - $94.5 $48,719 - $264,600	-2,800 Reduced 62.22%	1,700 $11,000
Q4 2023 Jan 18, 2024	BUY	$9.24 - $19.64 $41,580 - $88,380	4,500 New	4,500 $0
Q2 2023 Jul 18, 2023	SELL	$14.84 - $24.79 $83,104 - $138,824	-5,600 Reduced 53.85%	4,800 $0
Q1 2023 May 01, 2023	SELL	$8.08 - $17.33 $17,776 - $38,125	-2,200 Reduced 17.46%	10,400 $2,000
Q4 2022 Feb 07, 2023	BUY	$2.72 - $9.4 $34,272 - $118,440	12,600 New	12,600 $11,000
Q1 2022 Apr 14, 2022	BUY	$3.0 - $4.88 $2,700 - $4,392	900 New	900 $10,000
Q2 2020 Jul 22, 2020	SELL	$4.35 - $8.08 $87,000 - $161,600	-20,000 Closed	0 $0
Q1 2020 May 07, 2020	BUY	$3.45 - $7.95 $64,860 - $149,460	18,800 Added 1566.67%	20,000 $54,000
Q4 2018 Feb 05, 2019	SELL	$7.16 - $16.21 $74,464 - $168,584	-10,400 Reduced 89.66%	1,200 $6,000
Q3 2018 Nov 07, 2018	SELL	$9.7 - $19.65 $122,219 - $247,589	-12,600 Reduced 52.07%	11,600 $9,000
Q2 2018 Aug 10, 2018	BUY	$3.88 - $12.74 $93,896 - $308,308	24,200 New	24,200 $33,000

442

63.3M

6.23M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.83B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.